Letrozole
High Blood Pressure
ARKAY TherapeuticsSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the High Blood Pressure cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Recombinant Human Plasminogen Activator The George Institute | Phase 3 | B |
Aliskiren Novartis Pharmaceuticals | Phase 2 | CCC |
Dfn-15 ARKAY Therapeutics | Phase 1/2 | CCC |
Metformin ARKAY Therapeutics | Phase 1/2 | CCC |
NADOLOL Sandoz | Phase 1 | CC |
LAVENDER OIL Nilgün Erdoğan | N/A | D |
Eucalyptus globulus leaf essential oil Nilgün Erdoğan | N/A | D |
Same molecule, other indications
Letrozole is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →